Efficacy of the combination of tetracycline, amoxicillin, and lansoprazole in the eradication of Helicobacter pylori in treatment-naïve patients and in patients who are not responsive to clarithromycin-based regimens: A pilot study

Gut and Liver

Volumn 6, Issue 1, 2012, Pages 41-44

  Sezikli, Mesut ^a   Çetinkaya, Züleyha Akkan ^b   Güzelbulut, Fatih ^a   Yeşil, Atakan ^a   Altinöz, Mustafa Erhan ^a   Ulu, Nuriye ^c   Kurdaş, Ayşe Oya Övünç ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Department of General Surgery   (Turkey)

^c Karaman Provincial Health Directorate   (Turkey)

Author keywords

Helicobacter pylori; Rescue therapy; Tetracycline

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZATION; TASTE DISORDER; TREATMENT OUTCOME;

EID: 84856078205     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.1.41     Document Type: Article

References (21)

1. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA 1995;274:1064-1066.
2. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-1271. (Pubitemid 24129959)
3. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001;107:767-773. (Pubitemid 32274024)
4. Wilkinson M. Helicobacter pylori: an overview. Br J Biomed Sci 2001;58:59-60. (Pubitemid 32566032)
5. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-2379. (Pubitemid 29420659)
6. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
7. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001;96:1335-1339. (Pubitemid 32455056)
8. Kadayifçi A, Büyükhatipoǧlu H, Koruk M, et al. Efficacy of a proton pump inhibitor plus amoxicillin plus clarithromycin in the eradication of H. pylori in Turkey: a meta-analysis. Turk J Gastroenterol 2004;15(Suppl 1):5.
9. Güliter S, Keleş H, Ozkurt ZN, Cengiz DU, Kolukisa E. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol 2005;16:29-33. (Pubitemid 40570609)
10. Katzung BG. Basic & clinical pharmacology. New York: McGraw Hill, 2006:726-771.
11. Malfertheiner P, Megraud F, O'Morain C. Guidelines for the management of Helicobacter pylori infection: summary of the Maastricht-3 2005 Consensus Report. European Gastroenterology Review 2005. London: Touch Briefings, 2005.
12. Moder KA, Layer F, König W, König B. Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing. J Med Microbiol 2007;56(Pt 10):1370-1376. (Pubitemid 350105607)
13. Wu JY, Kim JJ, Reddy R, Wang WM, Graham DY, Kwon DH. Tetracycline- resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother 2005;49:578-583. (Pubitemid 40175665)
14. Baglan PH, Bozdayi G, Ozkan M, Ahmed K, Bozdayi AM, Ozden A. Clarithromycin resistance prevalence and Icea gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J Microbiol 2006;44:409-416. (Pubitemid 46657473)
15. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003;35:541-545. (Pubitemid 41070409)
16. Göral V, Zeyrek FY, Gül K. Antibiotic resistance in Helicobacter pylori infection. T Klin Gastroenterohepatol 2000;11:87-92.
17. Bakir Ozbey S, Ozakin C, Keskin M. Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains. Mikrobiyol Bul 2009;43:227-234.
18. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004;10:668-671. (Pubitemid 38351533)
19. Aydin A, Önder GF, Akarca US, et al. Efficacy of pantoprazole plus amoxicillin plus clarithromycin for 1 week and 2 weeks in the eradication of clarithromycin-sensitive and clarithromycin-resistant H. pylori. Turk J Gastroenterol 2004;15(Suppl 1):151.
20. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821-825. (Pubitemid 44356109)
21. Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003;18:815-820. (Pubitemid 37323647)